<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02107495</url>
  </required_header>
  <id_info>
    <org_study_id>A20-01</org_study_id>
    <nct_id>NCT02107495</nct_id>
  </id_info>
  <brief_title>Evaluation of the Samsung LABGEO IVD-A20 CHF Test in a Point-of-Care Setting</brief_title>
  <official_title>Evaluation of the Samsung LABGEO IVD-A20 CHF Test in a Point-of-Care Setting</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Electronics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nexus-Dx</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Samsung Electronics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To establish the performance characteristics of the Samsung LABGEO IVD-A20 CHF Test in
      intended use settings, by comparing test results of the A20 CHF Test with results obtained
      from an FDA-cleared comparator assay.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Optimize calibration
  </why_stopped>
  <start_date>March 2014</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion of clinically-confirmed CHF subjects for whom the Samsung LABGEO IVD-A20 CHF Test result was positive (clinical sensitivity).</measure>
    <time_frame>baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The proportion of non-CHF subjects for whom the LABGEO IVD A20 CHF Test result was negative (clinical specificity).</measure>
    <time_frame>baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Using a Passing-Bablok regression analysis, estimates of intercept and slope will be computed. Estimates of bias and corresponding 95% confidence interval for true bias at clinical decision threshold of 125mg/mL and 450 pg/mL will also be computed.</measure>
    <time_frame>baseline</time_frame>
    <description>Method comparison will be assessed using a Passing-Bablok regression analysis to determine the relationship between the Samsung LABGEO IVD-A20 CHF Test measurement in plasma and the corresponding measurement in plasma obtained from the comparator assay.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects with a positive LABGEO IVD-A20 CHF Test result, for whom a clinical diagnosis of CHF was confirmed (positive predictive value).</measure>
    <time_frame>baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects with a negative LABGEO IVD-A20 CHF Test result, for whom a clinical diagnosis of CHF was confirmed (negative predictive value).</measure>
    <time_frame>baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Computation of Receiver Operating Characteristic (ROC) curve and area under the curve (AUC) with 95% confidence interval for the true AUC.</measure>
    <time_frame>baseline</time_frame>
    <description>This analysis will assess the ability of the Samsung LABGEO IVD-A20 CHF Test to discriminate between confirmed CHF subjects and non-CHF subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variance components analysis will be conducted on data collected from each whole blood specimen undergoing point-of-care precision testing at study site. Estimates of within-run, between run, between day and total precision will be computed.</measure>
    <time_frame>10 days</time_frame>
    <description>The Samsung LABGEO IVD-A20 CHF Test result will be modeled as a function of testing days and runs, with replicates fully nested within runs, and runs fully nested within days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variance components analysis will be conducted on data collected from each plasma specimen undergoing point-of-care precision testing at study site. Estimates of within-run, between run, between day and total precision will be computed.</measure>
    <time_frame>20 days</time_frame>
    <description>The Samsung LABGEO IVD-A20 CHF Test result will be modeled as a function of testing days and runs, with replicates fully nested within runs, and runs fully nested within days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mixed model regression analysis will be conducted on each specimen type (whole blood vs. plasma) and storage condition.</measure>
    <time_frame>48 hours</time_frame>
    <description>The natural logarithm of the Samsung LABGEO IVD-A20 CHF Test measurement will be modeled as a linear function of time (in hours) after baseline testing.A separate linear function will be fitted to data collected from each study specimen and the intercepts and slops from individual specimens will be modeled as random effects.</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">191</enrollment>
  <condition>Congestive Heart Failure</condition>
  <arm_group>
    <arm_group_label>CHF-confirmed subjects</arm_group_label>
    <description>Subjects 21 years of age or greater with clinically confirmed heart failure or have presented to the clinical site with signs, symptoms and/or risk factors suggestive of heart failure.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects with potentially co-morbidities</arm_group_label>
    <description>non-CHF subjects 21 years or greater, with potentially confounding comorbidities such as diabetes, renal insufficiency, hypertension and chronic obstructive pulmonary disease (COPD).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Apparently healthy subjects</arm_group_label>
    <description>Apparently healthy subjects (meeting inclusion criteria) greater than 45 years of age, with no prior history of myocardial infarction (MI), acute coronary syndrome (ACS) congestive heart failure (CHF) or any other cardiac-related disease.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Samsung LABGEO IVD-A20 CHF Test</intervention_name>
    <arm_group_label>CHF-confirmed subjects</arm_group_label>
    <arm_group_label>Subjects with potentially co-morbidities</arm_group_label>
    <arm_group_label>Apparently healthy subjects</arm_group_label>
    <other_name>LABGEO IVD-A20 CHF Test, A20 CHF Test,</other_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Retaining plasma specimens
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects to be recruited for this study will be presenting to one of five point of care
        sites located in the USA. The sites will be emergency room or POL sites, and will include
        primary care facilities representative of those typically serving the intended use
        population for the test.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  CHF Subjects: 21 years of age or greater, with clinically confirmed CHF or have
             presented to the clinical site with signs, symptoms and/or risk factors suggestive of
             heart failure.

          -  Subjects with Potentially confounding comorbidities: Non-CHF subjects 21 years of age
             or greater, with potentially confounding comorbidities such as diabetes, renal
             insufficiency, hypertension and chronic obstructive pulmonary disease (COPD)

          -  Healthy Subjects: apparently healthy subjects greater than 45 years of age, with no
             prior history of cardiac-related disease.

        Exclusion Criteria:

          -  Apparently healthy subjects with a history of MI, CHF or other cardiac-related
             disease;

          -  Subjects with acute decompensated heart failure currently on nesiritide therapy;

          -  Subjects having participated in another experimental drug, biologic, or invasive
             device study within 30 days prior to signing informed consent for this study, or
             enrolled concurrently in any other investigative study; and

          -  Subjects unable to or refusing to provide written informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minneapolis Medical Research Foundation</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Manassas Clinical Research Center</name>
      <address>
        <city>Manassas</city>
        <state>Virginia</state>
        <zip>20110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 3, 2014</study_first_submitted>
  <study_first_submitted_qc>April 3, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2014</study_first_posted>
  <last_update_submitted>April 18, 2016</last_update_submitted>
  <last_update_submitted_qc>April 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CHF</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

